UP!
|
Type
|
Public |
|---|---|
| Traded as | NASDAQ: BRKS S&P 600 Component |
| Industry | Semiconductor Equipment & Materials |
| Founded | 1978 |
| Headquarters | Chelmsford, Massachusetts, United States |
|
Key people
|
Dr. Stephen S. Schwartz (CEO), Mark D. Morelli ( President and Chief Operating Officer) Lindon G. Robertson ( Chief Financial Officer) (Dec 31, 2013) |
| Revenue | $ 477.51M(Dec 31, 2013) |
|
Number of employees
|
1471 (Dec 31, 2013) |
| Website | www |
Dr. Stephen S. Schwartz (CEO), Mark D. Morelli ( President and Chief Operating Officer)
Brooks Automation was set up in 1978 and is now based in Chelmsford, Massachusetts. Brooks Automation is a provider of automation, vacuum and instrumentation equipment for multiple markets, including semiconductor manufacturing, technology device manufacturing and life sciences. Brooks Automation operates in four segments: Brooks Product Solutions, Brooks Global Services and Brooks Life Science Systems.
Brooks Automation was set up in 1978 and incorporated in 1994.
In 2002, Brooks Automation, Inc. completed the acquisition of Intelligent Automation Systems, Inc. of Cambridge, Massachusetts, a custom automation company with technology and products for the semiconductor, photonics and life sciences industries.
Brooks Automation acquired the Celigo automated Cell Cytometer product line from Cyntellect, Inc in 2011. The next year the company acquired intangible assets from Intevac, Inc. and acquired Crossing Automation Inc.
In October 2012, Brooks Automation entered into an agreement to acquire Crossing Automation Inc.
In April 2014, Brooks Automation entered into an agreement to sell its Granville-Phillips division to MKS Instruments.
Brooks closed the sale of Granville-Phillips to MKS Instruments on May 30, 2014.
Brooks Automation provides mainly four kinds: semiconductor automation and life science systems equipment, gas analysis and vacuum measurement, cryopumps, cryochillers and compressors, asset tracking equipment. The company features in developing and building the handling system and related technology. Automation products are used to support both atmospheric and vacuum based processes while the company's focus remains on improving performance and productivity. The company provides vacuum pumps and instrumentation to maintain pressure consistency of the known process gas. The Brooks Life Science Systems provides automated sample management systems and equipment, such as automated blood fractionation equipment, cellular imaging and consumables parts.
Brooks Automation won the R&D 100 award (100 most technologically significant new products introduced) by R&D Magazine for its Model 830 Vacuum Quality Monitor (VQMTM). VQMTM was used to determine gas composition with an electrostatic autoresonant ion trap.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q1 2022 | 2022-01-31 | Future report Set alerts | |
| Q4 2021 | 2021-11-10 | 0.78 | 0.78 |
| Q3 2021 | 2021-08-05 | 0.72 | 0.72 |
| Q2 2021 | 2021-05-10 | 0.61 | 0.61 |
| Q1 2021 | 2021-02-02 | 0.47 | 0.47 |
| Q4 2020 | 2020-11-10 | 0.00 | 0.00 |
| Q3 2020 | 2020-07-30 | 0.32 | 0.19 |
| Q2 2020 | 2020-04-30 | 0.25 | 0.12 |
| Q1 2020 | 2020-02-06 | 0.23 | 0.18 |
| Q4 2019 | 2019-11-06 | 0.24 | 0.07 |
| 2016-06-07 | Reiterated Rating | B. Riley | Buy | $16.50 |
| 2016-06-02 | Reiterated Rating | B. Riley | Buy | $16.50 |
| 2016-05-04 | Reiterated Rating | B. Riley | Buy | $16.50 |
| 2016-04-29 | Reiterated Rating | Credit Suisse | Sell | $9.80 |
| 2016-04-29 | Reiterated Rating | B. Riley | Buy | $16.50 |
| 2016-04-29 | Reiterated Rating | Credit Suisse Group AG | Sell | $9.80 |
| 2016-03-16 | Reiterated Rating | Credit Suisse | Underperform | $10.00 |
| 2016-03-14 | Reiterated Rating | B. Riley | Buy | $16.50 |
| 2016-03-09 | Reiterated Rating | B. Riley | Buy | $16.50 |
| 2016-03-08 | Lower Price Target | Credit Suisse | Underperform | $10.00 to $9.10 |
| 2016-03-04 | Reiterated Rating | B. Riley | Buy | $16.50 |
| 2016-02-09 | Reiterated Rating | B. Riley | Buy | $16.50 |
| 2016-02-04 | Lower Price Target | Credit Suisse | Underperform | $10.00 to $9.10 |
| 2016-02-04 | Boost Price Target | B. Riley | Buy | $15.50 to $16.50 |
| 2015-11-11 | Reiterated Rating | B. Riley | Buy | $15.50 |
| 2015-11-06 | Reiterated Rating | Needham & Company LLC | Buy | $14.00 to $13.00 |
| 2015-11-06 | Reiterated Rating | B. Riley | Buy | $15.50 |
| 2015-10-09 | Lower Price Target | Needham & Company LLC | Buy | $15.00 to $14.00 |
| 2015-08-14 | Reiterated Rating | Citigroup Inc. | Hold | $12.50 to $12.00 |
| 2015-08-12 | Reiterated Rating | B. Riley | Buy | $15.50 |
| 2015-08-07 | Reiterated Rating | B. Riley | Buy | $15.50 |
| 2015-06-29 | Initiated Coverage | Deutsche Bank | Hold | |
| 2015-06-29 | Initiated Coverage | Deutsche Bank AG | Hold | |
| 2015-05-01 | Reiterated Rating | B. Riley | Buy | $15.50 |
| 2015-02-06 | Reiterated Rating | B. Riley | Buy | $14.50 |
| 2015-01-20 | Reiterated Rating | Credit Suisse | Underperform | $10.00 |
| 2014-12-17 | Reiterated Rating | B. Riley | Buy | $14.50 |
| 2014-11-13 | Boost Price Target | Stifel Nicolaus | $15.00 | |
| 2014-11-05 | Downgrade | Sidoti | Buy to Neutral | |
| 2014-11-04 | Reiterated Rating | Citigroup Inc. | Neutral | $11.50 to $12.50 |
| 2014-10-07 | Initiated Coverage | Furey Research Partners | Buy | $17.00 |
| 2014-10-07 | Initiated Coverage | CRT Capital | Buy | $17.00 |
| 2014-06-27 | Upgrade | Stifel Nicolaus | Hold to Buy | $13.00 |
| 2014-05-27 | Upgrade | B. Riley | Neutral to Buy | $9.50 to $12.50 |
| 2014-05-09 | Lower Price Target | B. Riley | $10.50 to $9.50 | |
| 2014-04-22 | Reiterated Rating | Citigroup Inc. | Neutral | $11.50 |
| 2014-03-17 | Reiterated | Needham | Buy | $11 to $13 |
| 2014-03-17 | Boost Price Target | Needham & Company LLC | Buy | $11.00 to $13.00 |
| 2014-02-07 | Lower Price Target | Needham & Company LLC | $12.00 to $11.00 | |
| 2013-11-18 | Reiterated Rating | Citigroup Inc. | Neutral | $9.50 to $10.50 |
| 2013-11-15 | Reiterated | Northland Capital | Outperform | $11 to $12 |
| 2013-11-15 | Boost Price Target | Needham & Company LLC | Buy | $11.00 to $12.00 |
| 2013-11-15 | Boost Price Target | Northland Securities | Outperform | $11.00 to $12.00 |
| 2013-11-08 | Reiterated Rating | Northland Securities | Positive | |
| 2013-07-15 | Reiterated | Needham | Buy | $11 to $12 |
| 2012-10-02 | Downgrade | Barclays | Equal Weight to Underweight | |
| 2012-01-30 | Upgrade | Brigantine | Hold to Buy | $13.50 |
| 2011-06-29 | Reiterated | Needham | Buy | $15 to $13 |
| 2011-04-25 | Downgrade | Brigantine | Buy to Hold | |
| 2011-02-07 | Downgrade | Stifel Nicolaus | Buy to Hold | |
| 2010-10-11 | Initiated | Brigantine | Buy | $12 |
| 2010-09-07 | Downgrade | Barclays Capital | Overweight to Equal Weight | $13 to $6 |
| 2010-04-07 | Initiated | Brigantine | Buy | $12 |
| 2010-02-08 | Reiterated | Credit Suisse | Neutral | $6 to $6.50 |
| 2016-06-07 | Reiterated Rating | B. Riley | Buy | $16.50 |
| 2016-06-02 | Reiterated Rating | B. Riley | Buy | $16.50 |
| 2016-05-04 | Reiterated Rating | B. Riley | Buy | $16.50 |
| 2016-04-29 | Reiterated Rating | Credit Suisse | Sell | $9.80 |
| 2016-04-29 | Reiterated Rating | B. Riley | Buy | $16.50 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In BRKS 261 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| Vanguard Group, Inc | 7.07M |
| BlackRock Inc. | 7.04M |
| BlackRock Fund Advisors | 5.43M |
| KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC | 4.57M |
| Jackson Square Partners, LLC | 2.34M |
| MACQUARIE GROUP LTD | 2.24M |
| STATE STREET CORP | 2.00M |
| DF DENT & CO INC | 1.97M |
| BlackRock Institutional Trust Company, N.A. | 1.81M |
| BROWN ADVISORY INC | 1.69M |
| WADDELL & REED FINANCIAL INC | 1.45M |
| Global X Management CO LLC | 1.38M |
| JPMORGAN CHASE & CO | 1.37M |
| CONGRESS ASSET MANAGEMENT CO /MA | 1.34M |
| Conestoga Capital Advisors, LLC | 1.34M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| SCHWARTZ STEPHEN S President, CEO | 0.92% (617264) | BRKS / |
| HEADLEY MARTIN S EVP & Chief Financial Officer | 0.76% (506741) | BRKS / |
| Morelli Mark D EVP - Chief Operating Officer | 0.62% (414944) | BRKS / CMCO / |
| Steven A. Michaud SVP, Brooks Product Solutions | 0.33% (221215) | BRKS / |
| Robertson Lindon G EVP & Chief Financial Officer | 0.24% (158853) | BRKS / GTI / |
| Tenney Maurice H. President-Brooks Life Sciences | 0.23% (156798) | BRKS / PKI / |
| Haris Clinton M. SVP, Brooks Life Sciences | 0.23% (151374) | BRKS / ENTG / |
| Leitzke Thomas SVP, Global Operations | 0.21% (139819) | BRKS / |
| Montone William T. SVP, Human Resources | 0.19% (125847) | BRKS / |
| Mirchandani Kush SVP, Worldwide Sales | 0.18% (120792) | BRKS / |
| Joseph Jason VP, General Counsel, Secretary | 0.17% (116250) | BRKS / |
| WRIGHTON MARK S | 0.15% (102722) | BRKS / CBT / GLW / |
| Gray David C Chief Strategy & New Business | 0.14% (91806) | BRKS / |
| Palepu Krishna G. | 0.14% (91243) | BRKS / |
| MARTIN JOSEPH R | 0.13% (85468) | BRKS / CLCT / |
| WOOLLACOTT ALFRED III | 0.13% (85058) | BRKS / |
| ALLEN A CLINTON | 0.11% (75563) | BRKS / CLCT / LKQ / PMD / |
| Mathews Timothy S Principal Accounting Officer | 0.08% (55846) | BRKS / EIGI / |
| Pietrantoni David Principal Accounting Officer | 0.08% (52714) | BRKS / |
| Zane Ellen M | 0.07% (45750) | BRKS / BSX / HAE / PRXL / |
| PARK CHONG SUP | 0.05% (36645) | BRKS / CSC / ENPH / STX / |
| Jarzynka David Sr. VP, General Manager | 0.04% (25618) | BRKS / |
| MCGILLICUDDY JOHN K | 0.01% (9500) | BRKS / CBT / WTS / |
| Davis Robyn C | 0.01% (7134) | BRKS / |
UM